Literature DB >> 9209414

P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2.

J Wilson-Rawls1, J Liu, P Laneuville, R B Arlinghaus.   

Abstract

Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common beta c chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209414

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

2.  Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.

Authors:  Saradhi Mallampati; Xiaohong Leng; Haiqing Ma; Jianfang Zeng; June Li; Haiying Wang; Kevin Lin; Yue Lu; Yang Yang; Baohua Sun; Yun Gong; Ju-Seog Lee; Marina Konopleva; Michael Andreeff; Ralph B Arlinghaus; Zhen Cai; Bingliang Fang; Haifa Shen; Xin Han; Cheryl F Hirsch-Ginsberg; Xiaolian Gao; Anurag N Paranjape; Sendurai A Mani; Karen Clise-Dwyer; Xiaoping Sun
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

3.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

Review 4.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

5.  Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

Authors:  Chaofeng Mu; Xiaoyan Wu; Helen Ma; Wenjing Tao; Guodong Zhang; Xiaojun Xia; Jianliang Shen; Junhua Mai; Tong Sun; Xiaoping Sun; Ralph B Arlinghaus; Haifa Shen
Journal:  Mol Cancer Ther       Date:  2016-02-04       Impact factor: 6.261

6.  Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Authors:  Min Chen; Paolo Gallipoli; Donna DeGeer; Ivan Sloma; Donna L Forrest; Matthew Chan; Damian Lai; Heather Jorgensen; Ashley Ringrose; Hui Mi Wang; Karen Lambie; Helen Nakamoto; Kyi Min Saw; Ali Turhan; Ralph Arlinghaus; James Paul; Jon Stobo; Michael J Barnett; Allen Eaves; Connie J Eaves; Tessa L Holyoake; Xiaoyan Jiang
Journal:  J Natl Cancer Inst       Date:  2013-02-27       Impact factor: 13.506

7.  AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Authors:  Liang L Zhou; Yun Zhao; Ashley Ringrose; Donna DeGeer; Erin Kennah; Ann E-J Lin; Guoqing Sheng; Xiao-Jiang Li; Ali Turhan; Xiaoyan Jiang
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.